U.S. markets closed
  • S&P 500

    3,585.62
    -54.85 (-1.51%)
     
  • Dow 30

    28,725.51
    -500.10 (-1.71%)
     
  • Nasdaq

    10,575.62
    -161.89 (-1.51%)
     
  • Russell 2000

    1,664.72
    -10.21 (-0.61%)
     
  • Crude Oil

    79.74
    -1.49 (-1.83%)
     
  • Gold

    1,668.30
    -0.30 (-0.02%)
     
  • Silver

    19.01
    +0.30 (+1.62%)
     
  • EUR/USD

    0.9801
    -0.0018 (-0.19%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • GBP/USD

    1.1166
    +0.0043 (+0.38%)
     
  • USD/JPY

    144.7200
    +0.2770 (+0.19%)
     
  • BTC-USD

    19,147.61
    -170.71 (-0.88%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.84 (-1.83%)
     

Sage Therapeutics to Present at Upcoming August Investor Conferences

·1 min read

CAMBRIDGE, Mass., August 01, 2022--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the following upcoming investor conferences in August:

  • 2022 Wedbush PacGrow Healthcare Conference (Virtual): fireside chat on Tuesday, August 9, 2022 at 9:00 a.m. ET.

  • Canaccord Genuity 42nd Annual Growth Conference (Boston, MA): fireside chat on Wednesday, August 10, 2022 at 10:00 a.m. ET.

A live webcast of each event can be accessed on the Investor page of Sage’s website at investor.sagerx.com. A replay of the webcasts will be available approximately two hours after the completion of the events and will be archived for up to 30 days.

About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company fearlessly leading the way to create a world with better brain health. Our mission is to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive. For more information, please visit. www.sagerx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220801005269/en/

Contacts

Investor
Helen Rubinstein
315-382-3979
helen.rubinstein@sagerx.com

Media
Becky Kern
914-772-2310
becky.kern@sagerx.com